YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Vanda Pharmaceuticals (VNDA [https://seekingalpha.com/symbol/VNDA]) on Wednesday reported positive late-stage trial data for its sleep disorder therapy Hetlioz (tasimelteon) in adults with delayed sleep-wake phase disorder (DSWPD), setting…
Study met its primary endpoint: timing of sleep onset shifted 37.1 minutes earlier versus placebo (p=0.022) 60% of HETLIOZ® treated participants shifted sleep at least 30 minutes earlier, compared to 15% of the placebo arm WASHINGTON, Sept…
WASHINGTON, Aug. 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the NEREUS™ branded No. 47 entry from Rahal Letterman Lanigan Racing, driven by Mick Schumacher, is set to compete this weekend in the…
Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 4:30 p.m. ET CALL PARTICIPANTS President, Chief Executive Officer, and Chairman of the Board - Mihael Polymeropoulos Chief Financial Officer - Kevin Patrick Moran General Couns…
The National Psoriasis Foundation recognizes August as Psoriasis Awareness Month, an annual initiative aimed at raising awareness, educating the public and supporting efforts to improve the lives of people affected by psoriasis and psoriat…
Vanda Pharmaceuticals Inc. Q2 2026 Earnings Call Summary - Moby Strategic Execution and Performance Drivers Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's o…
(RTTNews) - Vanda Pharmaceuticals Inc. (VNDA) announced that the European Medicines Agency's Committee for Orphan Medicinal Products has issued a positive opinion recommending orphan drug designation for Imsidolimab, its investigational mo…
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is one of the Best Small-Cap Growth Stocks to Invest In Now. Recently, on June 4, H.C. Wainwright reiterated a Buy rating on Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) with a price target of $21. The…
The insomnia market is expected to increase throughout the study period due to several factors. Increased awareness of the disease has led to more cases being treated, contributing to market growth. Additionally, the rising number of clini…
(RTTNews) - Vanda Pharmaceuticals Inc. (VNDA), a biopharmaceutical company, announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted Imsidolimab orphan drug designation for the treatment of generalized pustular psor…
The Charcot–Marie–Tooth disease market is poised for steady growth, driven by increasing disease awareness and improved diagnostic capabilities. Advancements in genetic testing are enabling earlier and more accurate diagnosis, expanding th…
AnaptysBio, Inc. (NASDAQ:ANAB) is one of the best performing healthcare stocks so far in 2026. Piper Sandler cut the price target on AnaptysBio, Inc. (NASDAQ:ANAB) to $93 from $95 on May 4, reaffirming an Overweight rating on the shares. T…
Earnings Call Insights: Vanda Pharmaceuticals (VNDA) Q1 2026 MANAGEMENT VIEW * "Vanda delivered strong commercial execution in the first quarter, highlighted by 26% year-over-year growth in Fanapt sales, the groundbreaking U.S. launch of N…
Vanda Pharmaceuticals Inc. Q1 2026 Earnings Call Summary - Moby Strategic Performance and Commercial Evolution Fanapt growth of 26% year-over-year was primarily driven by the 2024 bipolar I disorder label expansion, which management identi…
Image source: The Motley Fool. DATE Wednesday, May 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS President, Chief Executive Officer, and Chairman of the Board — Mihael H. Polymeropoulos Senior Vice President and Chief Financial Officer — Kevin…
Seasoned pharmaceutical executive brings over 25 years of commercial leadership to Model N board REDWOOD CITY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Model N, a leading end-to-end commercialization, revenue optimization, and compliance p…
Health care stocks declined Monday afternoon, with the NYSE Health Care Index and the State Street H PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Incyte (INCY) came out with quarterly earnings of $1.81 per share, beating the Zacks Consensus Estimate of $1.38 per share. This compares to earnings of $1.16 per share a year ago. These figures are adjusted for non-recurring items. This q…
Geron Corporation (NASDAQ:GERN) is one of the best growth stocks under $10 to invest in. On April 13, Geron Corporation appointed Timothy Williams as Executive Vice President, Chief Legal Officer, and Corporate Secretary. A seasoned legal…
LOS ANGELES, April 20, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Vanda Pharmaceuticals, Inc., (“Vanda" or the "Company") (NASDAQ: VNDA) investors that the firm has initiated an investigation into possible securities fraud, and…
Health care stocks were mixed late Thursday afternoon, with the NYSE Health Care Index adding 0.1% a PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Health care stocks advanced Thursday afternoon, with the NYSE Health Care Index adding 0.3% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
(RTTNews) - Vanda Pharmaceuticals Inc. (VNDA) has called on the U.S. FDA to withdraw a legislative proposal included in the agency's FY 2027 Congressional Budget Justification. Proposal Details The FDA's proposal seeks to eliminate the cur…
AnaptysBio's (ANAB) board has approved the planned spin-off of First Tracks Biotherapeutics and a re PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
B. Riley raised the firm’s price target on Vanda Pharmaceuticals (VNDA) to $17 from $14 and keeps a Buy rating on the shares. Following BYSANTI’s approval, the firm’s revenue model for Vanda has been updated, reflecting expected growth in…
(RTTNews) - Vanda Pharmaceuticals Inc. (VNDA) on Wednesday said the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for imsidolimab for the treatment of Generalized Pustular Psoriasis (GPP), a r…
[Businesswoman analyzing forex and crypto chart data on futuristi] ismagilov/iStock via Getty Images Stock futures edged lower Monday morning to kick off February's final trading week, as investors assessed President Trump's new 15% across…
Rolls-Royce (RR.L) Engine maker Rolls-Royce (RR.L) was in the spotlight on Monday morning, after it was reported that the company plans to unveil a share buyback worth more than £1bn ($1.35bn) this week. Sky News reported that Rolls-Royce…
[US Food and Drug Administration (FDA)] * The U.S. FDA has approved Vanda Pharmaceuticals' (VNDA [https://seekingalpha.com/symbol/VNDA]) Bysanti (milsaperidone) for the treatment of bipolar I disorder and schizophrenia. * The company's sha…
Vanda Pharmaceuticals Inc. Q4 2025 Earnings Call Summary - Moby Strategic Performance and Market Dynamics Fanapt revenue growth of 24% was primarily driven by a 149% surge in new-to-brand prescriptions following the bipolar disorder commer…
Image source: The Motley Fool. Date Wednesday, February 11, 2026 at 4:30 p.m. ET Call participants President, Chief Executive Officer, and Chairman of the Board — Mihael H. Polymeropoulos Chief Financial Officer — Kevin Patrick Moran Gener…
Vanda Pharmaceuticals logo Key Points Fanapt drove commercial growth—full‑year Fanapt sales rose 24% to $117.3M (Q4 sales +25%), offsetting declines at Hetlioz which fell 7% for the year amid ongoing U.S. generic competition. Vanda reporte…
Gilead Sciences (GILD) came out with quarterly earnings of $1.86 per share, beating the Zacks Consensus Estimate of $1.83 per share. This compares to earnings of $1.9 per share a year ago. These figures are adjusted for non-recurring items…
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA). Such investors are advised to contact Danielle Peyton at newa…
(RTTNews) - As January 2026 comes to a close, it is time to reflect on the regulatory developments of the month and look ahead to what's in store in February. On January 13, 2026, Sentynl Therapeutics' Zycubo secured FDA approval, becoming…
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA). Such investors are advised to contact Danielle Peyton at newa…